- Older, opioid-naive patients with colorectal and lung cancer initially have higher rates of chronic opioid use than older people without cancer, but the gap narrows over time and is absent by 6 years postdiagnosis.
- Chronic opioid use was less likely among breast cancer survivors than matched control patients without cancer.
Why this matters
- Chronic opioid use among matched control patients increased from the first to the last year of the study period.
- 46,789 opioid-naive survivors of colorectal, lung, and breast cancers diagnosed between 2008 and 2013 and 138,136 noncancer control patients were evaluated.
- Chronic opioid use defined as ≥90 days of consecutive use.
- Funding: NIH.
- Chronic use among colorectal (OR, 1.34; 95% CI, 1.22-1.47), lung (OR, 2.55; 95% CI, 2.34-2.77) cancer survivors exceeded that of control patients in the first follow-up year.
- Colorectal cancer survivors with chronic opioid use were more likely vs control patients to have high-dose opioid use in the first 3 years of follow-up (ORs, from 1.79 to 2.61; all P<.05>
- Lung cancer survivors with chronic opioid use were more likely vs control patients to have high-dose opioid use for first the 4 years of follow-up (ORs, from 3.65 to 5.54; all P<.05>
- Chronic opioid use was less likely in breast cancer survivors.
- Patients with progressive/recurrent disease were included.
Coauthored with Antara Ghosh, PhD